Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer

Mol Cell Endocrinol. 2015 Dec 15:418 Pt 3:193-206. doi: 10.1016/j.mce.2015.04.017. Epub 2015 Apr 24.

Abstract

Prevailing wisdom is that estrogen receptor (ER)-α mediated genomic estrogen signaling is responsible for estrogen-stimulated cell proliferation and development of ER-positive breast cancer. However, accumulating evidence indicates that another estrogen signaling pathway, non-genomic or rapid estrogen signaling, also plays an important role in mitogenic estrogen signaling. Previously, our laboratory cloned a 36 kDa variant of ER-α, ER-α36, and found that ER-α36 is mainly expressed in the cytoplasm and at the plasma membrane. ER-α36 mediates rapid estrogen signaling and inhibits genomic estrogen signaling. In this review, we review and update the biological function of ER-α36 in ER-positive and -negative breast cancer, breast cancer stem/progenitor cells and tamoxifen resistance, potential interaction and cross-talk of ER-α36 with other ERs and growth factor receptors, and intracellular pathways of ER-α36-mediated rapid estrogen signaling. The potential function and underlying mechanism of ER-α in development of ER-positive breast cancer will also be discussed.

Keywords: Antiestrogen resistance; Breast cancer stem/progenitor cells; ER-positive and -negative breast cancer; ER-α36; Rapid estrogen signaling.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • Cell Membrane / metabolism
  • Cytoplasm / metabolism
  • Drug Resistance, Neoplasm
  • Estrogen Receptor alpha / genetics*
  • Estrogen Receptor alpha / metabolism*
  • Estrogens / metabolism
  • Female
  • Humans
  • Neoplastic Stem Cells / metabolism
  • Signal Transduction / drug effects
  • Tamoxifen / therapeutic use

Substances

  • Estrogen Receptor alpha
  • Estrogens
  • estrogen receptor alpha 36, human
  • Tamoxifen